-

$undefined

N/A

(N/A)

CalciMedica NasdaqCM:CALC CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops Auxora for the treatment of acute ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory indications. The company is based in La Jolla, California.

Location: 505 Coast Boulevard South, La Jolla, CA, 92037, United States | Website: https://calcimedica.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

8.634M

Cash

24.63M

Avg Qtr Burn

-5.327M

Short % of Float

2.18%

Insider Ownership

16.41%

Institutional Own.

57.55%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Auxora™ Details
Acute Pancreatitis

Phase 2b

Update

Auxora™ Details
Acute Kidney Injury, Kidney disease

Phase 2

Data readout

Auxora™ Details
Asparaginase-induced pancreatic toxicity

Phase 2

Update

GB-102 (Pan-VEGF inhibitor) Details
Eye disease , Wet age-related macular degeneration , Age-related macular degeneration

Failed

Discontinued

GB-102 (Pan-VEGF inhibitor) Details
Diabetes, Eye disease , Diabetic macular edema

Failed

Discontinued